Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05730816 · ClinicalTrials.gov registry record · Phase 2
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
A Phase 2 study of Mesothelioma, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT05730816 is a Phase 2 study of Mesothelioma that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 130 participants, below the 195-participant average among 46 other Mesothelioma trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05730816, a Phase 2 study of Mesothelioma, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .
Conditions Studied
Interventions
- DRUG Magnesium sulfate
- DRUG Normal Saline
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05730816
The ClinicalTrials.gov registry entry for NCT05730816 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 46 other Mesothelioma trials with a reported enrollment target (33% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Magnesium sulfate is the first listed.
NCT05730816 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05730816 about?
NCT05730816 is a clinical study titled "MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI". In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .
What is the current status of trial NCT05730816?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2023-04-04. Estimated completion is 2028-01-01.
What conditions does trial NCT05730816 study?
This clinical trial studies the following conditions: Mesothelioma.
What interventions are being tested in trial NCT05730816?
The interventions under investigation include: Magnesium sulfate (DRUG), Normal Saline (DRUG).
Who is sponsoring clinical trial NCT05730816?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05730816 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.